GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs... Show more
GMR Solutions shares have traded near the lower portion of their post-IPO range in recent weeks. The stock's most recent closing price of $10.99 sits roughly 3.7% above its level from about 30 days earlier, reflecting a market that has absorbed strong quarterly profit growth while weighing a softer revenue outlook and lingering cost pressures.
Following its third-quarter report, the stock sold off sharply in regular trading before paring losses in after-hours activity, a pattern that points to investor focus on guidance rather than the headline earnings beat. Broader healthcare-services sentiment has remained measured as reimbursement dynamics and inflation continue to shape expectations across the sector.
GMR Solutions operates as the largest provider of emergency medical services in the United States under the Global Medical Response brand. The company delivers emergent and non-emergent ground ambulance services, helicopter air ambulance transport, and mobile clinical services to roughly 5.5 million patients annually across markets representing more than 60% of the U.S. population.
The company's operating subsidiaries include American Medical Response (AMR), Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International. This integrated air-and-ground platform is a key competitive advantage, allowing GMR to coordinate care across geographies and service lines while holding a leading position in the emergency air medical transport segment. Investors follow GMRS for its defensive demand profile, national scale, and deleveraging story following its 2026 initial public offering.
GMR Solutions reported third-quarter results in early November, with revenue increasing 5.9% year over year to about $1.6 billion and adjusted EBITDA rising 4.2% to roughly $357 million. Net income more than doubled to $135.6 million, supported by stronger operating performance and lower interest expense following debt reduction. Emergent ground transports grew 3.4%, while the company's 911 Nurse Navigation offering expanded call volume by about 51%.
At the same time, management narrowed full-year revenue guidance and lowered the top end to approximately $6.05 billion, citing less favorable flying conditions and minimal hurricane deployments. Maintenance, fuel, and other direct expenses rose 25.1% during the quarter, partly driven by higher fuel costs tied to geopolitical developments and the timing of aircraft maintenance events.
On the capital front, GMR completed a repricing of its first-lien term loan in September, reducing its interest margin by 50 basis points and repaying approximately $200 million of debt. In late October, the company announced an additional order of Bell 407GXi helicopters from Textron (TXT), continuing a fleet modernization program aimed at improving instrument-flight capability and reducing weather-related disruptions.
Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant strategies appear in its curated Trending AI Robots section. These bots differ in trading style, timeframe, and performance metrics, giving users a way to compare algorithmic approaches across a range of market conditions. The section is designed to surface the strategies currently drawing the most attention and demonstrating the strongest recent results, rather than presenting an exhaustive list of every available bot. Investors interested in systematic, rules-based trading tools can review this page to see which AI-driven approaches are trending at any given time.
Looking ahead, investors will monitor whether GMR can sustain mid-single-digit revenue growth while defending margins against elevated fuel and wage inflation. Management has pointed to CPI-linked rate increases embedded in many contracts as a partial offset entering 2027, and expects favorable revenue estimate adjustments tied to No Surprises Act claims to trend lower over time.
Key items to watch include the pace of nurse navigation expansion and new-market contract wins, weather patterns affecting air transport capture rates, and ongoing reimbursement developments in Washington. Debt reduction remains a stated priority, with management targeting net leverage near 3.0x by the end of 2027. Regulatory scrutiny of emergency billing and private-equity ownership in healthcare also represents a longer-term factor for the company and the broader EMS industry.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Indicator for GMRS moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 1 instances where the indicator moved out of the overbought zone. In 1 of the 1 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMRS as a result. In 4 of 6 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for GMRS turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 4 similar instances when the indicator turned negative. In 4 of the 4 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GMRS moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for GMRS crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMRS advanced for three days, in 14 of 20 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
GMRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 9 of 14 cases where GMRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.851) is normal, around the industry mean (204.532). P/E Ratio (-6.129) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.502) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. GMRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement